Technical Analysis for AMRX - Amneal Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 8.53 0.29% 0.03
AMRX closed up 3.03 percent on Wednesday, November 6, 2024, on 3.34 times normal volume. It ran into resistance at its 50 day moving average.
Earnings due: Nov 8
*** please verify all earnings dates ***
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Flat Up

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.29%
50 DMA Resistance Bearish 0.29%
Pocket Pivot Bullish Swing Setup 0.29%
Volume Surge Other 0.29%
Bollinger Band Squeeze Range Contraction 0.29%
Gapped Up Strength 0.29%
MACD Bearish Centerline Cross Bearish 3.33%
Bollinger Band Squeeze Range Contraction 3.33%
BB Squeeze + Lower Band Touch Range Contraction 3.33%
Gapped Down Weakness 3.33%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 1 hour ago
Rose Above Previous Day's High about 1 hour ago
Up 1% about 1 hour ago
60 Minute Opening Range Breakout about 1 hour ago
Fell Below 10 DMA about 2 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amneal Pharmaceuticals, Inc. Description

Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Impax Generics and Impax Specialty Pharma. The Impax Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Impax Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Drugs Pharmaceutical Products Parkinson's Disease Treatment Of Parkinson's Disease Drug Products Headache Migraine Generic Drug Migraine Headache Treatment Of Migraine Migraine Headaches

Is AMRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.95
52 Week Low 3.72
Average Volume 595,660
200-Day Moving Average 6.84
50-Day Moving Average 8.51
20-Day Moving Average 8.51
10-Day Moving Average 8.46
Average True Range 0.22
RSI (14) 50.98
ADX 12.59
+DI 20.52
-DI 23.45
Chandelier Exit (Long, 3 ATRs) 8.29
Chandelier Exit (Short, 3 ATRs) 8.83
Upper Bollinger Bands 8.78
Lower Bollinger Band 8.24
Percent B (%b) 0.49
BandWidth 6.33
MACD Line -0.01
MACD Signal Line 0.01
MACD Histogram -0.0209
Fundamentals Value
Market Cap 2.61 Billion
Num Shares 307 Million
EPS 0.06
Price-to-Earnings (P/E) Ratio 141.67
Price-to-Sales 0.72
Price-to-Book 5.06
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.92
Resistance 3 (R3) 8.89 8.73 8.85
Resistance 2 (R2) 8.73 8.62 8.74 8.83
Resistance 1 (R1) 8.61 8.55 8.67 8.64 8.80
Pivot Point 8.45 8.45 8.48 8.46 8.45
Support 1 (S1) 8.33 8.34 8.39 8.36 8.20
Support 2 (S2) 8.17 8.27 8.18 8.17
Support 3 (S3) 8.05 8.17 8.15
Support 4 (S4) 8.08